{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-010609","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.961419+00:00","generated_at":"2026-06-17T10:30:32.243901+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bolt Biotherapeutics reports positive BDC-1001 Phase 1 data; advances to Phase 2; cash $192.8M","bullets":["BDC-1001 elicited objective responses including partial responses and stable disease across multiple HER2+ solid tumors as monotherapy and with nivolumab.","Phase 2 program to start in 2023: two studies in breast, colorectal, endometrial, and gastroesophageal cancers.","Entered clinical supply agreement with Roche for pertuzumab (Perjeta) to combine with BDC-1001 in breast cancer.","Cash, cash equivalents, and marketable securities of $192.8M as of Dec 31, 2022, expected to fund operations through 2025.","Full-year 2022 collaboration revenue $5.7M; R&D expenses $73.1M; loss from operations $90.3M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-010609","json":"https://secwatch.observer/filing/0000950170-23-010609.json","markdown":"https://secwatch.observer/filing/0000950170-23-010609.md","text":"https://secwatch.observer/filing/0000950170-23-010609.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000095017023010609/0000950170-23-010609-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000095017023010609/bolt-20230329.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T10:30:32.243901+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bc62ff2a590edb975b98fc7c55743423d4da2081","claim":"Bolt Biotherapeutics, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue Collaboration Revenue – Collaboration revenue was $1.4 million for the quarter and $5.7 million for the full year ended.","evidence_excerpt":"– 5:00 p.m. EDT Location: Orange County Convention Center, Section 24 Fourth Quarter and Full Year 2022 Financial Results • Collaboration Revenue – Collaboration revenue was $1.4 million for the quarter and $5.7 million for the full year ended December 31, 2022, compared to $0.5 million and $1.3 million for the same quarter and year in 2021. The collaboration","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641281/000095017023010609/0000950170-23-010609-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"Collaboration Revenue – Collaboration revenue was $1.4 million for the quarter and $5.7 million for the full year ended"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}